ABSTRACT
The incidence of prostate cancer has shown an obvious upward trend in recent years.18F-fluorodeoxyglucose(FDG)is a broad-spectrum imaging agent for cancer,but there is a " blind zone" in the application of prostate cancer.Therefore,exploring prostate imaging agents with better performance can help to make up the deficiency.At present,there are a number of positron imaging agents for prostate cancer,but the overall advantage is not obvious.Recently,a new imaging agent,68Ga-prostate specific membrane antigen(PSMA),has been demonstrated its better value in clinical application of prostate cancer.This review summarizes the research progress of 68 Ga-PSMA,
ABSTRACT
Objective To explore the synthesis of photographic developer 2-18 F-fluoropropionic acid(18 F-FPA) and its imaging value in prostate cancer-bearing nude mice.Methods 18F-FPA was automatically synthesized by using the CFN-multi-200 multifunctional drug synthesis module,then the quality control were performed.The PC3 prostate cancer-bearing nude mice models(16 cases) and 22RV1 prostate cancer-bearing nude mice models(4 cases) were constructed.Then 18F-FPA imaging was conducted in these models,which were compared with those by 2-deoxy-2-18 F fluoro-D-glueose(18 F-FDG) and 11C-choline for evaluating the imaging value of 18F-FPA in prostate cancer.The mice bearing PC3 prostate cancer were randomly divided into 4 group for conducting the biodistribution measurement.The percentage rate of injection dose per gram tissue(％ID/g) and tumor/non-tumor tissue ratio was calculated.Results The synthetic process of 18 F-FPA was about 40 min,the yield rate was (38 ± 2) ％ (without time correction),the radiochemical purity was more than 97 ％,with good in vitro stability.After 18F-FPA injection,the tumor image in two kinds of tumor-bearing nude micecould was developed clearly,while a slight uptake was detected in developed tumor with 18 F-FDG and n C-choline imaging.The biodistributions of tumor in PC3 prostate cancer bearing nude mice were (6.91 ± 0.72),(6.99 ±0.55),(7.17 ± 0.25),(6.49 ± 0.74) ％ ID/g at 0.5,1.0,2.0 and 4.0 h after 18 F-FPA injection,respectively,the difference was not statistically significant(P＞0.05).Conclusion 18 F-FPA is simply synthesized,has better imaging effect for the nude mice bearing prostate cancer and is expected to be used for clinical detection of prostate cancer.
ABSTRACT
Objective To evaluate the application value of 18 F‐FDG PET/CT in patients with fever of unknown origin (FUO) to improve the etiological diagnosis accuracy of PET/CT in patients with FUO and provide better service for clinical prac‐tice .Methods Clinical data and imaging results of 144 cases of FUO patients diagnosed through 18 F‐FDG PET/CT examination in Wuhan union hospital from December 2009 to December 2011 were retrospectively analyzed .The final diagnoses were based on sur‐gical pathology ,aspiration cytology ,or discharge diagnosis combined with more than 12 months of follow‐up results .All the PET/CT images were analyzed and the clinical application value of PET/CT in FUO patients were evaluated through the diagnose rate , diagnose efficiency and clinical staging of malignant tumor .Results Among the 144 patients ,there were 130 cases ultimately had clear diagnosis ,which including 41 cases of malignant tumor ,89 cases of benign lesions and 14 cases the cause of unknown .PET/CT detected abnormal lesions for 97 .6% (40/41) of patients with malignant lesions and 88 .7% (79/89) of patients with benign le‐sions ,and the diagnostic sensitivity ,specificity ,accuracy ,positive predictive value ,and negative predictive value were :97 .6% (40/41) ,86 .5% (77/89) ,90% (117/130) ,76 .9% (40/52) and 98 .7% (77/78) .PET/CT detected the primary lesions for the first time in 46 .3% (19/41) patients with malignant tumor ,and detected more lesions than the traditional imaging methods in 92 .7% (38/41) of these patients .Conclusion 18 F‐FDG PET/CT imaging can provided important reference value for the detection of primary lesions ,the qualitative diagnosis of benign and malignant lesions and clinical staging of malignant lesions .